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Abstract
Background: Tuberculosis (TB) is a disease which kills two million people every year and infects approximately over one-
third of the world’s population. The difficulty in managing tuberculosis is the prolonged treatment duration, the emergence
of drug resistance and co-infection with HIV/AIDS. Tuberculosis control requires new drugs that act at novel drug targets to
help combat resistant forms of Mycobacterium tuberculosis and reduce treatment duration.
Methodology/Principal Findings: Our approach was to modify the naturally occurring and synthetically challenging
antibiotic thiolactomycin (TLM) to the more tractable 2-aminothiazole-4-carboxylate scaffold to generate compounds that
mimic TLM’s novel mode of action. We report here the identification of a series of compounds possessing excellent activity
against M. tuberculosis H37Rv and, dissociatively, against the b-ketoacyl synthase enzyme mtFabH which is targeted by TLM.
Specifically, methyl 2-amino-5-benzylthiazole-4-carboxylate was found to inhibit M. tuberculosis H37Rv with an MIC of
0.06 mg/ml (240 nM), but showed no activity against mtFabH, whereas methyl 2-(2-bromoacetamido)-5-(3-chlorophe-
nyl)thiazole-4-carboxylate inhibited mtFabH with an IC50 of 0.9560.05 mg/ml (2.4360.13 mM) but was not active against the
whole cell organism.
Conclusions/Significance: These findings clearly identify the 2-aminothiazole-4-carboxylate scaffold as a promising new
template towards the discovery of a new class of anti-tubercular agents.
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Introduction
The disease tuberculosis (TB), once considered eradicated, has
again become a major global health concern. M. tuberculosis, the
causative organism, produces a chronic infection in the lungs that
can become disseminated. Over the past decade, at least 30
million individuals have died from the disease and estimates
indicate that one-third of the world’s population is infected with
latent or persistent M. tuberculosis. Moreover, globally more than 8
million people develop active TB every year, and if trends
continue there will be a total of 36 million disease-related deaths
by the year 2020 [1,2].
The resurgence in the disease is caused by an inadequate and
extended chemotherapy that relies on drugs developed in the mid-
twentieth century. The associated poor patient compliance and
emergence of drug resistant forms of TB, coupled with a strong
epidemiological co-existence with HIV/AIDS highlights the
fundamental need for new, more effective drugs to treat the
disease [3–5].
The mycobacterial cell wall of M. tuberculosis is rich with many
unique key structural components that are necessary for the
mycobacteria to survive and grow within the human host, and has
long been a target for anti-TB drug development. Essential to the
cell wall are the mycolic acids, which are high molecular weight 2-
alkyl, 3-hydroxy fatty acids that exist in several forms of differing
chemical functionality. Indeed, the first line anti-tubercular drug
isoniazid (INH) works by inhibiting their biosynthesis. The
complete sequencing of the TB genome [6] has revealed
significant biochemical and genetic insight into mycolic acid
biosynthesis that will aid the search for new druggable targets.
These unique lipids are biosynthesised by both fatty acid synthase
enzyme systems I and II (FAS I and FAS II) to produce C56–64
meromycolic acids and the C26 a-branch [7,8] after a series of
biostransformations [9,10].
The naturally occurring antibiotic thiolactomycin 1 (TLM,
figure 1) [11–13] primarily acts by inhibiting the FAS-II b-
ketoacyl-ACP synthase condensing enzymes, halting mycolic acid
biosynthesis and subsequently to M. tuberculosis cell death [14–17].
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TLM is also orally available and non-toxic in the mouse model,
which makes it an attractive compound for development.
Conversely, the chemical scaffold of TLM possesses a chiral
centre at the 5-position which makes the synthesis of series of TLM
analogues lengthy and costly, and complicates the optimisation
process. Such factors need to be considered carefully when
developing economically viable drugs for developing countries.
This issue of synthetic tractability has focused researchers’
efforts towards the synthesis of either racemic analogues or
derivatives that contain simple modifications, and has yielded
limited improvements in activity against M. tuberculosis and modest
activity against mtFabH [18–22]. We have focussed on identifying
alternative, easily accessible 5-membered ring isosteres to generate
large compound libraries targeted against the condensing enzyme
mtFabH and M. tuberculosis. Herein, we demonstrate that 2-
aminothiazole-4-carboxylate offers a promising template for the
development of new anti-tubercular agents, and report the design
and synthesis of methyl 2-amino-5-benzylthiazole-4-carboxylate 2
as our most potent inhibitor of M. tuberculosis H37Rv, with an MIC
of 0.06 mg/ml (0.24 mM), which is more effective than both TLM
and INH (MICs of 13 mg/ml (62.5 mM) [18] and 0.25 mg/ml
(1.8 mM) [19] respectively (figure 1). We also show that methyl 2-
(2-bromoacetamido)-5-(3-chlorophenyl)thiazole-4-carboxylate 3
inhibits mtFabH with an IC50 of 0.95 mg/ml (2.43 mM), which
compares well with TLM 1 and its most potent analogue 4 (IC50
values of 16 mg/ml (75 mM) and 1.1 mg/ml (3.0 mM) respectively
[22] (figure 1).
Results and Discussion
Ligand design
The initial focus of our ligand design was based on the active
site geometry and mechanism of action of the target enzyme
mtFabH, a homodimer (PDB: 1M1M) that converts C12–20 acyl-
CoA substrates to the corresponding b-ketoacyl-AcpM product
after reaction with mal-AcpM in a two step process [23]. At the
molecular level, the acyl-CoA substrate enters an ‘‘L’’ shaped
binding pocket consisting of a lateral and longitudinal channel,
with the active site catalytic triad of Cys112-His244-Asn274
located at the junction. Transacylation of the Cys122 residue
occurs when the adjacent His244 deprotonates the thiol group
(directly or via a molecule of water, as postulated by Brown et al.
[23]) to generate a thiolate nucleophile that attacks the carbonyl
group of the acyl chain occupying the longitudinal channel, and
releases CoA-SH from the lateral channel through which the
substrate entered. The second substrate, mal-AcpM, then enters
the lateral channel, and is decarboxylated by the catalytic residues
His244 and Asn274, and condensed with the thioester formed at
Cys112 to generate the b-ketoacyl-AcpM, which also dissociates
via the lateral channel. Recently, Sachdeva et al. have postulated
that the overall reaction may occur simultaneously in both active
sites of the dimer [24].
As no inhibitor-mtFabH co-crystal structures have been solved
to date, we investigated the binding pattern of TLM with the
closely related analogue ecFabB from E.coli [25]. TLM reversibly
inhibits ecFabB by forming a number of non-covalent interactions:
the methyl group at carbon 3 of TLM is positioned in a
hydrophobic pocket defined by residues Phe229 and Phe392; the
5-isoprenoid moiety is wedged between two peptide bonds - from
above by residues Val271 and Phe272 and from below by Gly391
and Phe392, which are important for specificity [23]; the carbonyl
oxygen forms two H-bonds with the two histidines in the active
site; the 4-hydroxyl group H-bonds to the carbonyl oxygen of
Val270 and the amide NH of Gly305 through a lattice of three
water molecules; and the sulfur is adjacent to the active site Cys
residue, although without any obvious interaction. The strong H-
bonding between the active site His residues of ecFabB and the
TLM carbonyl group is believed to be crucial for effective
inhibitory activity against this enzyme. Based on this analysis, we
postulated that the closely related active site of mtFabH could be
expected to form an equivalent H-bonding network with TLM,
and any new isosteric scaffold would need to maintain many of
these important interactions. The equivalent condensing enzyme
from E. coli (ecFabH) is also closely related to mtFabH, and has
been co-crystalised with the very potent inhibitor 2-hydroxy-6-(3-
phenoxy-4-phenyl-benzamido) benzoic acid [26]. This complex
revealed an important role for a carboxylic acid moiety in the
ligand as it forms specific interactions in the active site with the
His250 residue from ecFabH [26]. We considered inclusion of this
moiety to be important for our inhibitors and proposed the achiral
2-amino thiazole-5-carboxylate scaffold as an alternative to the
TLM substructure to combine pharmacodynamic potency with
essential pharmacokinetic considerations such as solubility. Finally,
synthetic tractability and subsequent diverse library generation
were considered possible using the simple procedure described by
Barton et al. [27].
Using GOLD, docking studies were performed to investigate
the poses for our scaffold in the mtFabH active site [28]. We
observed that the carboxyl group of the thiazole ring forms H-
bonds with the NH of Cys112, whilst the NH2 is proximal to and
H-bonds with the imidazole ring of His244. This allowed us to
generate a hypothetical template for the development of inhibitors
of mtFabH (Figure 2A). Further docking studies were carried out
with phenyl, m-chlorophenyl (figure 2B) and benzyl substituents in
the 5-position in both the 4-methyl ester and free acid forms of the
thiazoles. In these cases, the longitudinal channel appears to be the
preferred residence for the 5-substituents, whilst the 2-amino
group and potentially amide derivatives thereof could be
accommodated in the lateral channel. We also noted that a 2-
bromoacetamido substituent in this position would place the thiol
group of Cys112 in a position to become alkylated via a
nucleophilic SN2 reaction, and could lead to irreversible inhibition
of the enzyme (figure 2C). Whilst such a strategy would normally
be performed once a selective and relatively potent inhibitor had
Figure 1. The chemical structures of thiolactomycin 1, its analogue 4, and inhibitors 2 and 3.
doi:10.1371/journal.pone.0005617.g001
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been found, we postulated that it would be reasonable at this early
stage of inhibitor design to attempt this in order to establish if
ligand inhibition was at all possible before addressing selectivity in
later rounds of ligand optimisation. Based on this rationale, we
prepared a series of thiazoles that included the substituents studied
for evaluation against the enzyme and M. tuberculosis.
Chemical Synthesis
Using the flexible synthetic procedure described by Barton et al.
[27], the synthesis of the thiazole derivatives (figure 3) was
achieved starting with the Darzens reaction between methyl
dichloroacetate 5 and the appropriate aldehyde. This afforded a
mixture of the a-chloro glycidic ester and b-chloro a-oxoester,
which was extracted with diethylether and immediately reacted
with thiourea dissolved in methanol to generate the methyl ester
thiazoles 2, 6–8. To investigate whether a free carboxylic acid
functionality would increase binding within the active site through
facilitating electrostatic interactions proposed by the modeling
studies, we hydrolysed the esters with 0.1 M sodium hydroxide
solution followed by workup with dilute hydrochloric acid to
generate compounds 9–12. In order to generate 2-bromoaceta-
mido analogues, the free amines 2, 6–12 were reacted with 2-
bromoacetylchloride in anhydrous THF at 0uC to afford the
amides 3, 13–15. As described previously, hydrolysis with 0.1 M
sodium hydroxide gave the corresponding carboxylic acids 16–19
for comparison.
In vitro structure activity relationships
Inhibition of mtFabH. The compounds were first assessed
against the target enzyme mtFabH using the procedure developed
by Brown et al. [23] (figure 4). Despite many of them not
demonstrating any inhibitory activity at a concentration of
200 mg/ml, it was pleasing to see that the bromoacetamido
analogues that were prepared to facilitate an SN
2 type substitution
between the ligand and the Cys112 residue, were active. The
bromoacetamido esters 3, 14 and 15 inhibited the enzyme with
IC50 values of 0.9560.05 (2.4360.13 mM), 1.160.1 mg/ml
(3.2260.29 mM) and 5961.1 mg/ml (159.863.0 mM)
respectively, whilst the corresponding carboxylic acid 19
inhibited the enzyme at 22562.81 mg/ml (71868.97 mM).
Interestingly, the ester 13 and carboxylic acids 16, 17 and 18
failed to inhibit the enzyme.
It is clear that whilst the electrophilic bromomethyl substituent
establishes activity against the enzyme, its effect is modified by
Figure 2. The modeling studies of the 2-aminothiazole-4-carboxylate analogues with mtFabH. (A) The hypothetical template of the 2-
aminothiazole-4-carboxylates for mtFabH inhibitor development. This illustrates the key H-bonding interactions with the catalytic triad amino acid
residues. (B) The binding pose of methyl 2-amino-5-methylthiazole-4-carboxylate in the active site of mtFabH showing the NH2 group proximal to His
244 and directed towards the lateral channel, with the 5-methyl group directed towards the longitudinal channel. (C) The binding pose of methyl 2-
(2-bromoacetamido)-5-(3-chlorophenyl)thiazole-4-carboxylate with the bromomethylene portion in the vicinity of the Cys112 thiol group.
doi:10.1371/journal.pone.0005617.g002
Figure 3. Synthesis of the 2-aminothiazole-4-carboxylate analogues.
doi:10.1371/journal.pone.0005617.g003
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different substituents at the 4- and 5- positions. Assuming that the
inhibition observed involves reaction with the Cys112 residue,
then the ligands must be situated in the vicinity of the catalytic
triad. As the longitudinal and lateral tunnels are composed of
lipophilic amino acid residues, we suggest that 13 and 16, which
possess methyl groups at position 5, are unable to maximize the
hydrophobic interactions with these channels necessary to
facilitate enzyme inhibition. However, inserting a phenyl group
at position 5 and augmenting it with a m-Cl, as in 14 and 3
respectively, enables the appropriate hydrophobic interactions
with the enzyme to occur and enables effective inhibition. The
flexibility of the ligand also appears to be an important factor; the
m-Cl phenyl carboxylic acid analogue 18 is inactive whereas its 5-
benzyl counterpart 19, which is less lipophilic, inhibits the enzyme
with an IC50 of 22562.81 mg/ml (71868.97 mM). Comparison
with its benzyl ester 15, which inhibits mtFabH with an IC50 of
5961.1 mg/ml (159.863.0 mM), suggests that both hydrophobic-
ity and flexibility at the 5-position of the thiazole ring are
instrumental in orientating the ligand to achieve effective
inhibition. It is interesting that 13 fails to inhibit mtFabH as it
appears that the free acids are weaker inhibitors than the esters.
This may be accounted for by the molecule possessing a methyl
group at position 5 which does not enable it to maximize the
hydrophobic interactions necessary to bind to the enzyme.
Conversely, such interactions may be permitted by the flexible
benzyl substituent on the free acid 19 which enables weak
inhibition.
Inhibition of M. tuberculosis H37Rv. Whilst it was
encouraging to find that a small number of compounds inhibited
the target enzyme, it was important to know if this activity would
lead to inhibition of the whole cell organism. From the data
obtained it was clear that all of the bromoacetamido analogues
failed to inhibit M. tuberculosis H37Rv (figure 4). We do not know, at
this stage, whether these compounds did not inhibit the
Figure 4. The in vitro activity and molecular properties of the 2-aminothiazole-4-carboxylates. a, b Compounds regarded as not active (N/
A) if no inhibition is observed at 200 mg/ml. c FAS-I/II assay conducted at 200 mg/ml and compounds regarded as not active is ,50% inhibition
observed. d AlogP and logD calculated using Pipeline Pilot (SciTegic) software. eFrom reference [18]. fFrom reference [22].
doi:10.1371/journal.pone.0005617.g004
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mycobacteria through an inability to access the target enzyme due
to inappropriate physicochemical properties, or because the
bromomethyl moiety was chemically or metabolically inactivated
by the Mycobacterium.
In contrast to the 2-bromoacetamido analogues, four of the free
amine compounds (2, 6, 9 and 11) inhibited M. tuberculosis H37Rv
with MIC values of 0.06, 16, 0.06 and 32 mg/ml (0.24, 93, 0.35
and 125 mM) respectively, whilst the other analogues of this group
showed no activity. Given that these compounds did not inhibit
mtFabH, their mechanism of action must involve other targets
within the organism.
Although these compounds exhibit excellent activity, in the
absence of any recognisable trends in the series, it is difficult to
ascertain clear structure activity relationships. The best activity
was obtained with 2 with a benzyl group in the 5-position and a
methyl ester in the 4-position, whereas the carboxylic acid
analogue was shown to be inactive. The opposite observations
were seen with the inactive methyl ester analogue 8 possessing an
m-Cl phenyl group at the 5-position and the corresponding active
acid 11. A similar trend was observed for the 5-methyl analogues 9
and 6 with MIC values of 0.06 and 16 mg/ml (0.35 and 93 mM)
respectively. We speculate that these observations may result from
the compounds’ ability to enter the cell. In all cases, the primary
amine at the 2-position would be associated with a dissociation
equilibrium at physiological pH which could penetrate cellular
membranes in the unionized state. Compounds 9 and 11 on the
other hand, with both carboxylic acid and amino substituents,
would exist as zwitterions and would not normally be expected to
penetrate the lipophilic cell wall. The uptake of these compounds
could involve a cellular uptake mechanism, such as mycobacterial
porins that the inactive zwitterionic compounds 10 and 12 are not
substrates for. The inactivity of the 2-amino analogue 7 is more
likely due to its inability to interact structurally with the target in
the organism.
Specificity of the 2-amino thiazole-4-carboxylates. The
molecules under investigation were designed to inhibit mtFabH in
the mycobacterial FAS-II system, with selectivity over the related
mammalian FAS-I system. To examine selectivity, the compounds
were assessed using the procedures of Brown et al. [23] and
Slayden et al. [13].
No inhibition of the FAS enzymes was observed, either as the
acid or ester, when the 2-position was the free amine (figure 5).
These data support the possibility that activity against M.
tuberculosis H37Rv of compounds 2, 6, 9 and 11 involves a target
other than mtFabH, or indeed the other FAS-II enzymes.
However, with the exception of 15 all of the compounds
possessing the bromoacetamido group at the 2-position showed
activity against the FAS enzymes although no obvious trends were
observed across this series. This is perhaps not surprising as these
compounds may be inhibiting other enzymes in the FAS-II system
or indeed at different sites in the multifunctional FAS-I complex.
However, it was evident from the data that the phenyl 14 and m-
Cl-phenyl 3 analogues were the only compounds active against
mtFabH and selective against FAS-II. The mtFabH inhibitor 19
inhibited both FAS-I and FAS-II, whereas 16 inhibited only FAS-
II and 18 FAS-I. Intriguingly, compound 15 failed to inhibit the
FAS enzymes although inhibited mtFabH with an IC50 of
5961.1 mg/ml (159.863.0 mM). While 15 may have shown
activity against purified mtFabH, its inhibitory potential against
mtFabH in the crude FAS-II assay may be difficult to detect as the
related enzyme KasA (present in the crude reaction mix) has been
shown to have FabH-type activity and could have had a
compensatory effect [17].
Cytoxicity was investigated against human foreskin fibroblast
HS-27 cells (Figure 5) to establish toxicity profiles for our
compounds. The results indicated that none of the 2-amino
analogues or the free carboxylic analogues of the bromoacetamido
compounds showed significant cytotoxicity at a concentration of
100 mg/ml. Conversely, the carboxylic esters of the bromoaceta-
mido compounds 3, 13, 14 and 15 all showed signs of significant
cytotoxicity. We speculate that this may be due to the
indiscriminate alkylation of essential cellular components rather
than the increased ability of these esters to penetrate the cells over
the carboxylic acids. This is supported by the fact that the non-
cytotoxic acids 17, 18 and 19 have comparable logD values to
those of the cytotoxic esters 13, 14 and 15 and thus possess similar
physicochemical characteristics.
Considerations for future development of the 2-
aminothiazole-4-carboxylate scaffold
Our data clearly indicate that the 2-aminothiazole-4-carboxyl-
ate scaffold offers a promising new lead for further development.
Methyl 2-amino-5-benzylthiazole-4-carboxylate 2 inhibits M.
tuberculosis with an MIC of 0.06 mg/ml (240 nM) and is not
cytoxic against HS-27 cells at 100 mg/ml concentrations. These
compounds do not appear to inhibit the enzyme mtFabH, and it is
important that their mode of action is elucidated for optimisation
of the ligand to be carried out effectively. In doing so, care must be
Figure 5. The cytotoxic effects of the compounds against HS-27 human fibroblast cells. The data indicates that only the carboxyl esters of
the bromoacetamido analogues were toxic.
doi:10.1371/journal.pone.0005617.g005
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taken to retain the non-toxic and oral bioavailability properties of
the molecule. However, whilst the zwitterionic, low molecular
weight compound 9 has a structure that is highly hydrophilic,
which has implications for both absorption and excretion by
patients, this should be viewed in the context of INH, a successful
and routinely administered anti-TB drug, which also has a low
molecular weight and a logP value of 21.1.
Materials and Methods
Computational methods
Definition of active site. The active site determines the
volume taken into consideration during the docking process and
was defined as all protein atoms within 20 A˚ of the sulphur atom
of Cys112.
Ligand and protein flexibility. All rotatable bonds of the
ligand were randomized at the beginning of the GOLD docking
and treated as completely flexible during the docking runs. Bond
lengths, angles and torsions associated with non-rotatable bonds in
the ligand were fixed in their initial configurations. The protein in
GOLD is normally treated as rigid, with partial flexibility applied
to hydroxyl protons and NH3
+ groups, to allow rotation for
hydrogen bond optimization.
GOLD docking. For each independent genetic algorithm
(GA) run, a maximum number of 100,000 operations were
performed on a population of 5 islands of 100 individuals.
Operator weights for crossover, mutation and migration were set
to 95, 95 and 10 respectively. Limits for van der Waals contacts
and hydrogen bonds were assigned as 4.0 A˚ and 2.5 A˚ respectively
and ‘‘GOLD Score’’ was chosen to assess the fitness of docked
ligand-protein poses. Fifty poses were saved and visualized inside
the active site to provide incite into potential binding patterns.
Water molecules were removed from the pdb file and ligands were
docked directly without any further preparation of the protein as
recommended by the vendor.
Experimental methods
Reagents and apparatus. Melting point determination was
performed using a Stuart Scientific Melting Point SMP1 apparatus
with degrees Celsius (uC) as the unit. Infra-red spectra were run on
Jasco FT-IR-4200 ATR (Attenuated Total Reflection Mode) and
Mattson Genesis Series FT-IR spectrometers with samples
compressed with KBr into disks. Wavenumbers, (n max) are
expressed as cm21. Proton nuclear magnetic resonance (1H
NMR) and carbon (13C NMR) spectra were run on JEOL EX
270 (270 MHz), Bruker AMX-400 (400 MHz) and JEOL Lambda
delta 400 (400 MHz) spectrometers. Chemical shifts are stated in
parts per million (ppm) and multiplicity indicated as singlet (s),
doublet (d), triplet (t), quartet (q), and multiplet (m). Coupling
constants (J) are quoted in Hertz (Hz) and deuterated solvents
specified for each of the compounds. High-resolution mass
spectroscopy (MS) was obtained using Fourier transform
electrospray ionisation (FTMS-ESI) and fast atom bombardment
(3-nitrobenzyl alcohol matrix) (FAB-NOBA) ionizations on a JEOL
JMS-700 Dual-sector High-resolution Mass Spectrometer. Mass to
charge ratio (m/z) and relative abundance stated for molecular ion
radicals is M+.. Unless otherwise stated, all reagents and solvents
were obtained from commercial sources. Solvents were dried
according to standard procedures when deemed necessary.
Synthesis of methyl 2-amino-5-benzylthiazole-4-
carboxylate (2) as a general method for the synthesis of 2-
amino-5-derivatized 4-carboxylate thiazoles (General
procedure A). Phenylcetaldehyde (1.6 g, 36 mmol, 1.0eq) was
added to a stirring solution of methyl dichloroacetate 5 (5 g,
36 mmol, 1.0eq) dissolved in anhydrous ether (150 ml) at 0uC
before adding NaOMe (1.65 g, 54 mmol, 1.5eq) dissolved in
anhydrous MeOH (20 ml) dropwise over a period of 45 minutes.
The mixture was allowed to stir for a further one hour at 0uC
before adding brine (150 ml), extracting the organic phase with
ether (150 ml), drying over MgSO4, and reducing in vacuo. To the
crude residue was added thiourea (1.9 g, 36 mmol, 1.0eq)
dissolved in MeOH (100 ml) and the mixture refluxed for
4 hours before concentrating in vacuo and neutralizing with
concentrated ammonium hydroxide solution. The mixture was
washed with dichloromethane (DCM) (36, 50 ml), dried over
anhydrous MgSO4, and purified by re-crystallization using
chloroform and methanol (1:3) to give 2 as a yellow powder
(4.0 g, 44.9%). m.p 92–94uC; 1H NMR (270 MHz, DMSO-d6) d
3.74 (s, 3H), 4.32 (s, 2H), 7.02 (s, 2H), 7.32 (m, 5H); 13C NMR
(270 MHz, DMSO-d6) d 31.7, 51.0, 126.1, 127.9, 128.8, 135.5,
136.4, 139.7, 162.3, 164.3; umax (cm
21): 3465, NH stretch, amine;
1711, C = O stretch; FAB/NOBA-MS calculated C12H13N2O2S
(M+H) 249.0698, found 249.0696.
Synthesis of methyl 2-(2-bromoacetamido)-5-(3-
chlorophenyl)thiazole-4-carboxylate (3) as a general proce-
dure for the synthesis of the bromoacetamido derivatives
(general procedure B). Compound 8 (3.0 g, 17.4 mmol,
1.0eq) was added to a stirring solution of anhydrous
tetrahydrofuran (THF) (100 ml) and triethylamine (TEA) (3.5 g,
34.8 mmol, 2.0eq) at 0uC before adding acetyl chloride (3.45 g,
17.4 mmol, 1.0eq) dropwise over a period of 30 minutes. The
mixture was left to stir for a further 30 minutes at 0uC before
allowed to warm to room temperature for one hour. THF was
reduced in vacuo and the crude residue was re-dissolved in a
mixture of DCM and water before the pH of the solution was
adjusted to 3.0 using 0.1 M HCl. The mixture was washed with
DCM (3650 ml), dried over anhydrous MgSO4, and purified by
re-crystallization using chloroform and methanol (1:6) to give 3 as
a white powder (1.4 g, 33.1%). m.p 218–220uC. 1H NMR
(400 MHz, DMSO-d6) d 3.80 (s, 3H), 4.11 (s, 2H), 7.36–7.39 (m,
3H), 7.47 (s, 1H); 13C NMR (400 MHz, DMSO-d6) d 27.7, 52.2,
128.4–131.7, 134.2, 139.0, 156.0, 162.3, 164.9; umax (cm
21) 3216,
NH stretch, 1699, C = O stretch, conjugated ester; 1684, C = O
stretch, primary amide; FTMS-ESI calculated C13H11N2O3SClBr
(M+H) 388.9362, found 388.9323.
Methyl 2-amino-5-methylthiazole-4-carboxylate (6). The
title compound was obtained as a pale yellow powder (1.7 g,
38.3%) using general procedure A. m.p 165–168uC. 1H NMR
(270 MHz, DMSO-d6) d 2.49 (s, 3H), 3.70 (s, 3H), 6.97 (s, 2H);
13C NMR (270 MHz, DMSO-d6) d 12.7, 52.1, 135.2, 137.1,
164.3, 167.5; umax (cm
21) 3433, NH stretch, amine; 1688, C = O
stretch, conjugated ester; FTMS-ESI calculated C6H9N2O2S
(M+H) 173.0385, found 173.0379.
Methyl 2-amino-5-phenylthiazole-4-carboxylate (7). The
title compound was obtained as a pale yellow powder (1.7 g,
20.4%) using general procedure A. m.p 218–221uC. (Lit: 223uC)
[28]. 1H NMR (270 MHz, DMSO-d6) d 3.65 (s, 3H), 7.25 (s, 2H),
7.29–7.39 (m, 5H); 13C NMR (270 MHz, DMSO-d6) d 128.35,
128.68, 129.88, 131.65, 131.98, 137.54, 164.19, 166.13; umax
(cm21) 3411, NH stretch, amine; 1696, C = O stretch, conjugated
ester. FAB/NOBA-MS calculated C11H11N2O2S (M+H)
235.0541, found 235.0545.
Methyl 2-amino-5-(3-chlorophenyl)thiazole-4-carboxylate
(8). The title compound was obtained as a pale yellow powder
(2.3 g, 50.7%) using general procedure A. mp 229–232uC. 1H
NMR (400 MHz, DMSO-d6) d 3.70 (s, 3H), 7.76 (m, 3H), 7.81 (s,
1H); 13C NMR (400 MHz, DMSO-d6) d 52.0, 128.19, 128.8,
129.01, 129.95, 130.54, 132.68, 133.13, 136.1, 162.26, 166.1;
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umax (cm
21) 3417, NH stretch; 1699, C = O stretch; FAB/NOBA-
MS calculated C11H10N2O2SCl (M+H) 269.0152, found
269.0163.
Synthesis of 2-amino-5-methylthiazole-4-carboxylic acid
(9) as a general method for the hydrolysis of 2-amino-5-
derivatized 4-carboxylic acid thiazoles (general procedure
C). Compound 6 (1.0 g, 6.3 mmol, 1.0eq) was added to a
stirring solution of NaOH (150 ml, 85 mM) at 50–60uC over a
period of 30 minutes before a clear solution formed, cooled and
acidified with 1 M HCl to pH 3–4. A precipitate was formed and
collected in a Buchner funnel, which was re-crystallized using
methanol to give 9 (0.8 g, 75.0%). mp 320–324uC; 1H NMR
(270 MHz, DMSO-d6) d 2.49 (s, 3H), 6.97 (s, 2H);
13C NMR
(270 MHz, DMSO-d6) d 12.7, 135.2, 137.1, 164.3, 167.5; umax
(cm21) 3433, NH stretch, amine; 1688, C = O stretch, ester; 1688,
COO stretch, carboxylic acid; FTMS-ESI calculated C5H7N2O2S
(M+H) 159.0228, found 159.02138.
2-amino-5-phenylthiazole-4-carboxylic acid (10). The
title compound was obtained as a white needle-like crystals
(2.4 g, 70%) using general procedure C. mp 242–243uC; 1H NMR
(400 MHz, DMSO-d6) d 7.2 (bs, 1H), 7.35 (m, 4H), 12.5 (bs, 1H);
13C NMR (400 MHz, DMSO-d6) d 128.35, 128.68, 129.88,
131.66, 131.98, 137.54, 164.2, 166.13; umax (cm
21) 3364, NH
stretch, primary amine; 1701, C = O stretch, carboxylic acid;
FTMS-ESI calculated C10H9N2O2S (M+H) 221.0385, found
221.0377.
2-amino-5-(3-chlorophenyl)thiazole-4-carboxylic acid (11).
The title compound was obtained as a white powder (2.4 g, 63.3%)
using general procedure C. mp 242–244uC; 1H NMR (400 MHz,
DMSO-d6) d 7.30–7.37 (m, 3H), 7.48 (s, 1H);
13C NMR (400 MHz,
DMSO-d6) d 128.2, 129.02, 131.4, 133.2, 134.0, 138.2, 163.9, 166.5;
umax (cm
21) 3274, NH stretch, primary amine; 1684, C = O stretch,
carboxylic acid; FAB/NOBA-MS calculated C10H8N2O2SCl (M+H)
254.9995, found 254.9982.
2-amino-5-benzylthiazole-4-carboxylic acid (12). The
title compound was obtained as a yellow powder (0.6 g, 68.0%)
using general procedure C. m.p 300–302uC; 1H NMR (400 MHz,
DMSO-d6) d 4.32 (s, 2H), 7.02 (s, 2H), 7.32 (m, 5H);
13C NMR
(400 MHz, DMSO-d6) d 32.6, 127.0, 128.8, 129.06, 136.4, 137.6,
140.9, 164.2, 165.1; umax (cm
21) 3465, NH stretch, amine; 1711,
C = O stretch, carboxylic acid.; FAB/NOBA-MS calculated
C11H11N2O2S (M+H) 235.0541, found 235.0529.
Methyl 2-(2-bromoacetamido)-5-methylthiazole-4-carboxy-
late (13). The title compound was obtained as an off-white powder
(2.6 g, 53.7%) using general procedure B. mp 220–222uC; 1H NMR
(400 MHz, DMSO-d6) d 2.62 (s, 3H), 3.79 (s, 3H), 4.12 (s, 2H), 12.8
(s, 1H); 13C NMR (400 MHz, DMSO-d6) d 12.66, 28.7, 52.19, 135.9,
138.7, 153.7, 163.0, 166.0; umax (cm
21) 3235, NH stretch, primary
amide; 1717, C = O stretch, conjugated ester; 1699, C = O stretch,
primary amide; FTMS-ESI calculated (M+H) 292.9595, found
292.9582.
Methyl 2-(2-bromoacetamido)-5-phenylthiazole-4-carboxy-
late (14). The title compound was obtained as a brown powder
(0.8 g, 47.9%) using general procedure B. mp 218–220uC; 1H NMR
(400 MHz, DMSO-d6) d 3.69 (s, 3H), 4.16 (s, 2H), 7.48 (m, 5H),
13.08 (s, 1H); 13C NMR (400 MHz, DMSO-d6) d 28.6, 52.3, 128.9–
130.5, 135.1, 139.5, 155.6, 162.6, 166.4; umax (cm
21) 3230, NH
stretch, primary amide; 1697, C = O stretch, conjugated ester; 1697,
C = O stretch, primary amide; FAB/NOBA-MS calculated
C13H12BrN2O3S (M+H) 354.9752, found 354.9752.
Methyl 5-benzyl-2-(2-bromoacetamido)thiazole-4-carboxy-
late (15). The title compound was obtained as a brown powder
(1.5 g, 34.5%) using general procedure B. mp 218–220uC; 1H NMR
(400 MHz, DMSO-d6) d 3.96 (s, 3H), 4.05 (s, 2H), 4.54 (s, 2H), 7.32
(m, 5H), 9.90 (s, 1H); 13C NMR (400 MHz, DMSO-d6) d 28.6, 32.5,
52.3, 127.3, 129.11, 129.25, 135.6, 140.5, 143.2, 154.7, 163.5, 166.0;
umax (cm
21) 3231, NH stretch, primary amide; 1701, C = O stretch,
conjugated ester; 1701, C = O stretch, primary amide; FAB/NOBA-
MS calculated C14H14N2O3SBr (M+H) 368.9908, found 368.9902.
2-(2-Bromoacetamido)-5-methylthiazole-4-carboxylic acid
(16). The title compound was obtained as an off-white powder
(0.7 g, 73.5%) using general procedure C. mp 218–220uC; 1H
NMR (400 MHz, DMSO-d6) d 2.65 (s, 3H), 4.11 (s, 2H), 12.8 (s,
1H); 13C NMR (400 MHz, DMSO-d6) d 12.77, 28.82, 137.0, 138.5,
153.0, 164.0, 166.0; umax (cm
21) 3185, NH stretch, primary amide;
1699, C = O stretch, carboxylic acid; 1662, C = O stretch, primary
amide. FTMS-ESI calculated C7H8BrN2O3S (M+H) 278.9439,
found 278.9425.
2-(2-Bromoacetamido)-5-phenylthiazole-4-carboxylic acid
(17). The title compound was obtained as a brown powder
(0.1 g, 18.6%) using general procedure C. mp 208–210uC; 1H
NMR (400 MHz, DMSO-d6) d 4.16 (s, 2H), 7.41 (m, 5H);
13C
NMR (400 MHz, DMSO-d6) d 28.7, 128.8, 129.21, 130.31, 137.8,
139.1, 155.0, 164.0, 167.0; umax (cm
21) 3216, NH stretch, primary
amide; 1675, C = O stretch, carboxylic acid; 1675, C = O stretch,
primary amide. FAB/NOBA-MS calculated C12H10BrN2O3S
(M+H) 340.9595, found 340.9600.
2-(2-Bromoacetamido)-5-(3-chlorophenyl)thiazole-4-carboxy-
lic acid (18). The title compound was obtained as a white powder
(0.3 g, 37.2%) using general procedure C. mp 228–230uC; 1H NMR
(400 MHz, DMSO-d6) d 4.17 (s, 2H), 7.46 (m, 3H), 7.61 (s, 1H);
13C
NMR (400 MHz, DMSO-d6) d 28.6, 114.98, 123.96, 128.46, 129.04,
131.32, 133.59, 136.7, 137.2, 155.7, 163.4, 166.4; umax (cm
21) 3180,
NH stretch, primary amide; 1679, C = O stretch, carboxylic acid; 1679,
C = O stretch, primary amide. FAB/NOBA-MS calculated
C12H9N2O3S (M+H) 374.9206, found 374.9194.
5-Benzyl-2-(2-bromoacetamido)thiazole-4-carboxylic acid
(19). The title compound was obtained as a brown powder (0.3 g,
33.3%) using general procedure C. mp 220–222uC; 1H NMR
(400 MHz, DMSO-d6) d 4.10 (s, 2H), 4.49 (s, 2H), 7.32 (m, 5H),
12.80 (s, 1H); 13C NMR (400 MHz, DMSO-d6) d 28.7, 32.5,
127.24, 129.08, 129.21, 136.8, 140.3, 142.4, 154.3, 164.0, 166.0;
umax (cm
21) 3185, NH stretch, primary amide; 1695, C = O stretch,
carboxylic acid; 1661, C = O stretch, primary amide; FTMS-ESI
calculated C13H12N2O3SBr (M+H) 354.9752, found 354.9736.
mtFabH inhibition assay. The condensing activity of
mtFabH was assayed by mixing 100 mM holo-AcpM, 1 mM b-
mercaptoethanol, 0.1 M sodium phosphate buffer pH 7.0, 50 mM
malonyl-CoA, 45 nCi of [2-14C]malonyl-CoA (specific activity
53 Ci/mol), 12.5 mM of palmitoyl-CoA, and 0.3 mg mtFabD in a
final volume of 40 ml. The mtFabD protein was added to generate
the malonyl-AcpM substrate for the reaction in situ. A mixture of
AcpM, 1 mM b-mercaptoethanol, and the buffer was incubated at
37uC for 30 min to ensure complete reduction of AcpM, and then
the remaining components (except mtFabH) were added. The
mixture was then dispensed into microcentrifuge tubes along with
the test compound (0.5–200 mg/ml), and the reaction was initiated
by the addition of 0.5 mg of mtFabH. The reaction mixture was
held at 37uC for 40 min. The reaction was quenched by adding
5 mg/ml NaBH4 in 100 mM K2HPO4, 100 mM KCl, 30%
tetrahydrofuran, resulting in the liberation of b-ketoacyl groups
from their respective thioesters as acyl-1,3-diols. These products
were extracted three times with 2 ml of water-saturated toluene,
and the extracts were pooled and washed with an equal volume of
water. The organic component was transferred to scintillation
vials, the solvent was removed by evaporation, 5 ml EcoScintA
(National Diagnostics, UK) was added, and the radiolabeled
products were quantified by liquid scintillation counting.
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FAS-I and FAS-II Assays. FAS-I and FAS-II experiments
were conducted as per Slayden et al. (1996) using the 40–80%
ammonium sulphate fraction. The standard reaction mixture for
the incorporation of radioactivity from [2-14C]malonyl-CoA into
C16 to C24 fatty acids catalysed by FAS-I was composed as follows:
100 mM Tris.HCl pH 7.9, 5 mM EDTA, 5 mM dithiothreitol,
300 mM acetyl-CoA, 100 mM NADPH, 100 mM NADH, 1 mM
flavin mononucleotide, 500 mM a-cyclodextrin, 300 mM CoA-SH,
100,000 cpm of [2-14C] malonyl-CoA (specific activity 53 Ci/
mol), test compound (0.5–200 mg/ml) and 2 mg of cytosolic
enzyme preparation in a total volume of 500 ml. Similarly, the
standard reaction mixture for incorporation of radioactivity from
[2-14C]malonyl-CoA into C24 to C30 fatty acids catalysed by FAS-
II contained the following: 100 mM potassium phosphate buffer
(pH 7.0), 5 mM EDTA, 5 mM dithiothreitol, 10 mM palmitoyl-
CoA, 140 mM NADPH, 140 mM NADH, 100 mg of AcpM,
40 mM malonyl-CoA, 200,000 cpm of [2-14C]malonyl-CoA
(specific activity 53 Ci/mol), test compound (0.5–200 mg/ml)
and 200 mg of cytosolic enzyme preparation in a total volume
of 250 ml. In both the FAS-I and FAS-II assays, reactions were
performed in triplicate at 37uC for 30 min and terminated by the
addition of 250 ml of 20% potassium hydroxide in 50% methanol
at 100uC for 45 min. Following acidification with 150 ml of 6 M
HCl, the resultant 14C-labelled fatty acids were extracted three
times with petroleum ether. The organic extracts were pooled,
washed once with an equal volume of water, and dried in a
scintillation vial prior to counting.
M. tuberculosis H37Rv inhibition assays. All compounds
were screened for their in vitro antimycobacterial activity against
M. tuberculosis H37Rv by an in-house broth macrodilution method.
The activity of compounds was confirmed by MIC determination
by different methods against M. tuberculosis H37Rv, which
included: broth microdilution assay, resazurin microdilution
assay, agar dilution proportion method and the MB/Bactec 3D
system. Positive and negative growth controls were run in each
experiment run and ciprofloxacin was used as an antibiotic control
(MIC = 0.025–0.5 mg/ml would indicate that the experiment is
successful). Unless stated otherwise, the inoculum was 100 ml of 1
McFarland broth during log phase. A 21 gauge fine-needled
syringe was used to flush the broth 5 times to break up any clumps.
Blood agar plates were inoculated to check contamination. Here is
a brief description of each method:
Broth macrodilution assay. A stock solution of each
compound (1 mg/ml) was diluted in sterile distilled water to test
the range (0.06–32 mg/ml). Each tube contained 4 ml sterile
Middlebrook 7H9 broth containing albumin-dextrose-catalase
(ADC supplement, Oxoid), Tween 80, glycerol and 4 ml of the
compound solution was added to make serial double dilutions.
Tubes were incubated at 37uC for 7 days and then read visually.
MIC was determined as the lowest concentration of antibiotic that
prevented turbidity.
Resazurin microdilution assay. 96-well microtitre plates
with U-bottomed wells (Nunclon, Denmark) were used and stock
solutions (1 mg/ml) were diluted to four fold the final highest
concentration tested [29]. Three ranges were tested in duplicate:
0.2–0.025 mg/ml, 0.3–0.037 mg/ml and 0.5–0.06 mg/ml. A two-
fold dilution series was prepared with 100 ml antibiotic solution in
sterile distilled water. The microtitre plates were covered with lids
and placed inside a safety box (Nalgene, USA) and incubated at
37uC for seven days. On the seventh day, 30 ml resazurin (prepared
as 0.01% and store at 4uC until use within one week) was added and
incubated at 37uC for another 24 h. Plates were read on the
following day and MIC was determined as the lowest concentration
of antibiotic that prevented colour change (blue to pink).
Microdilution broth assay. Microdilution broth assay was
performed simultaneously with the resazurin assay using same
method but without the 1:20 dilution step. The MIC was determined
after fourteen days by reading the microtitre plate visually.
Agar proportion method. The MIC of each compound was
tested by agar dilution in triplicate as recommended by the
National Committee for Clinical Laboratory Standards (NCCLS).
The compounds dilution range was (0.3–0.025 mg/ml) and stock
solutions were diluted to tenfold the final highest concentration
tested. Plates were prepared as by adding 2 ml of the compound
solution to 18 ml of Middlebrook 7H10 agar containing oleic acid-
albumin-dextrose-catalase supplement (OADC, Oxoid), sealed
and stored at 4uC to be used within one week of preparation. Each
plate was inoculated with 20 ml 1 McFarland broth in the log
phase diluted to different concentrations (1021 to 1026 dilutions).
Plates were incubated at 37uC for fourteen days. The MIC was
considered the lowest concentration that showed no visible
colonies at all dilutions.
MIC measurement by MB/Bactec 3D system. Stock
solutions of the compounds were prepared as 10,000 times the
desired concentration and diluted accordingly with the liquid
medium provided in the MB bottles. Each bottle was inoculated
with 0.5 ml Middlebrook 7H9 broth culture in the log phase with
growth of 1.0 McFarland turbidity. A positive (1%) and a negative
control and isoniazid control were included. Bottles were kept in
the automated system for 56 days. MIC was considered as the
lowest concentration of compound that did not grow or gave
growth signal later than the (1%) control.
HS27 toxicity studies. The HS27 cells (grown in Dulbecco’s
modified eagle medium, supplemented with FBS, penicillin/
streptomycin, L-glutamine and sodium pyruvate (Invitrogen) were
plated in 96 well plates from Helena Bioscience at 1610e4 cells
per well (80 ul/well) and incubated for 24 hrs at 37uC, 5% CO2.
The samples (10 ul/well) and alamar blue (10 ul/well) were
added, the cells incubated in the presence of sample at 37uC, 5%
CO2 for 24 hrs before reading in the fluorescence mode (560/
590 nm).
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